{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-012899","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2025-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.627277+00:00","generated_at":"2026-05-24T15:54:45.058335+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Zentalis reports azenosertib ORR ~35% and mDOR 6.3 months in Cyclin E1+ PROC; Part 2 initiation on track for 1H2025","bullets":["Azenosertib demonstrated ORR of 34.9% (15/43) in response-evaluable Cyclin E1+ PROC patients; mDOR 6.3 months (95% CI: 2.7–NE) as of Jan 13, 2025 cutoff.","Cyclin E1 overexpression by IHC identified as predictive biomarker; ~50% of PROC patients overexpress Cyclin E1.","Safety profile consistent; most common TRAEs were GI toxicities and fatigue; 21.6% discontinued due to TRAEs.","Initiation of DENALI Part 2 in 1H 2025 on track; registration-intent topline data expected by year end 2026.","Preclinical data show synergistic antitumor effects of azenosertib combined with microtubule inhibitor-based ADCs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-012899","json":"https://secwatch.observer/filing/0001628280-25-012899.json","markdown":"https://secwatch.observer/filing/0001628280-25-012899.md","text":"https://secwatch.observer/filing/0001628280-25-012899.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000162828025012899/0001628280-25-012899-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000162828025012899/zntl-20250315.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T15:54:45.058335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}